Vertex Pharmaceuticals Inc (VRTX)
422.78
+3.79
(+0.90%)
USD |
NASDAQ |
May 10, 16:00
422.82
+0.04
(+0.01%)
After-Hours: 20:00
Vertex Pharmaceuticals Accounts Receivable (Quarterly): 1.793B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.793B |
December 31, 2023 | 1.563B |
September 30, 2023 | 1.539B |
June 30, 2023 | 1.556B |
March 31, 2023 | 1.548B |
December 31, 2022 | 1.442B |
September 30, 2022 | 1.385B |
June 30, 2022 | 1.333B |
March 31, 2022 | 1.293B |
December 31, 2021 | 1.137B |
September 30, 2021 | 1.100B |
June 30, 2021 | 929.14M |
March 31, 2021 | 977.55M |
December 31, 2020 | 885.40M |
September 30, 2020 | 791.92M |
June 30, 2020 | 791.77M |
March 31, 2020 | 845.27M |
December 31, 2019 | 633.52M |
September 30, 2019 | 443.32M |
June 30, 2019 | 464.90M |
March 31, 2019 | 438.30M |
December 31, 2018 | 409.69M |
September 30, 2018 | 379.76M |
June 30, 2018 | 393.44M |
March 31, 2018 | 327.29M |
Date | Value |
---|---|
December 31, 2017 | 281.34M |
September 30, 2017 | 263.49M |
June 30, 2017 | 247.95M |
March 31, 2017 | 207.96M |
December 31, 2016 | 200.36M |
September 30, 2016 | 182.23M |
June 30, 2016 | 189.36M |
March 31, 2016 | 181.88M |
December 31, 2015 | 173.84M |
September 30, 2015 | 165.27M |
June 30, 2015 | 94.52M |
March 31, 2015 | 80.33M |
December 31, 2014 | 75.96M |
September 30, 2014 | 114.31M |
June 30, 2014 | 81.84M |
March 31, 2014 | 59.86M |
December 31, 2013 | 85.52M |
September 30, 2013 | 120.28M |
June 30, 2013 | 164.87M |
March 31, 2013 | 194.05M |
December 31, 2012 | 143.25M |
September 30, 2012 | 139.63M |
June 30, 2012 | 185.62M |
March 31, 2012 | 232.23M |
December 31, 2011 | 183.14M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
443.32M
Minimum
Sep 2019
1.793B
Maximum
Mar 2024
1.123B
Average
1.119B
Median
Accounts Receivable (Quarterly) Benchmarks
Amgen Inc | 6.776B |
Eli Lilly and Co | 7.886B |
Regeneron Pharmaceuticals Inc | 5.222B |
Alpine Immune Sciences Inc | 0.167M |
Editas Medicine Inc | 0.245M |